Passage Bio, Inc. Stock Price, News & Analysis

Passage Bio (NASDAQ: PASG) announced that Will Chou, M.D., president and CEO, will participate in a fireside chat at the Guggenheim Securities 2nd Annual Healthcare Innovation Conference on Wednesday, November 12, 2025 at 9:30 a.m. ET in Boston.

A live webcast will be available on the company’s Investors & News website at investors.passagebio.com, and a replay will be available for 90 days following the event.

Passage Bio (NASDAQ: PASG) announced that Will Chou, M.D., president and chief executive officer, will participate in a panel at the Chardan 9th Annual Genetic Medicines Conference on Tuesday, October 21, 2025 at 3:30 p.m. ET in New York City.

A live webcast will be available on the company’s Investors & News webpage at investors.passagebio.com, and a replay will be accessible for 90 days following the event.

Passage Bio (NASDAQ: PASG), a clinical-stage genetic medicines company specializing in neurodegenerative diseases, announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York City.

CEO Will Chou, M.D., will deliver a company overview presentation and the management team will engage in one-on-one investor meetings. The presentation will be available via video webcast to conference attendees starting September 5, 2025, at 7:00 a.m. ET, with a 30-day replay period accessible through the company's investor relations website.

Passage Bio (NASDAQ: PASG) has reported Q2 2025 financial results and clinical progress for its FTD-GRN program. The company completed dosing of Cohort 2 in the upliFT-D study, with PBFT02 showing promising results including durable elevation in CSF progranulin levels and improved disease progression biomarkers compared to natural history.

Financial highlights include a cash position of $57.6 million, reduced R&D expenses to $5.8M from $10.4M YoY, and a narrowed net loss of $9.4M compared to $16.0M YoY. The company's cash runway extends into Q1 2027.

Key upcoming milestones include seeking regulatory feedback on manufacturing process in 2H 2025 and trial design in 1H 2026, along with reporting updated interim data from Dose 2 in 1H 2026.

Passage Bio (NASDAQ:PASG), a clinical-stage genetic medicines company, has announced a 1-for-20 reverse stock split effective July 14, 2025. The split will reduce outstanding common shares from approximately 62.4 million to 3.1 million.

The reverse split aims to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share. The move was approved by stockholders at the 2025 annual meeting on May 28. Stockholders will not need to take action, as positions will be automatically adjusted, with fractional shares rounded up to the nearest whole share.

The company's trading symbol "PASG" will remain unchanged, though a new CUSIP number (702712 209) will be assigned.

Passage Bio (NASDAQ: PASG) reported updated interim data from their Phase 1/2 upliFT-D clinical trial of PBFT02, a one-time gene therapy for frontotemporal dementia with granulin mutations (FTD-GRN). The treatment demonstrated robust and durable elevation in CSF progranulin levels, with Dose 1 patients showing sustained increases through 18 months post-treatment. Notably, Dose 2, at 50% lower concentration, achieved substantial CSF PGRN elevation reaching healthy adult ranges. The therapy showed promising results in slowing disease progression, with treated patients experiencing only a 4% increase in plasma NfL levels at 12 months compared to 28-29% increases in untreated patients. While most adverse events were mild to moderate, three patients experienced serious adverse events. The company plans to amend the trial protocol to include prophylactic anticoagulation and modify inclusion criteria for earlier-stage patients. Passage Bio remains on track for regulatory feedback on pivotal trial design in 1H 2026.

Passage Bio (NASDAQ: PASG) reported Q1 2025 financial results and clinical progress. The company treated its first FTD-GRN patient with Dose 2 PBFT02 and enrolled a second patient, with more being evaluated. Dose 2 is 50% lower than Dose 1 due to robust CSF progranulin expression achieved. The company also opened enrollment for FTD-C9orf72 patients in the upliFT-D study. Financially, PASG reported cash of $63.4 million, extending runway into Q1 2027. Q1 2025 net loss was $15.4 million ($0.25/share), improved from $16.7 million ($0.30/share) in Q1 2024. R&D expenses decreased to $7.7 million from $11.5 million year-over-year. The company plans to report interim safety and biomarker data from Dose 2 and 12-month data from Dose 1 patients in H2 2025.

Passage Bio (NASDAQ: PASG) reported its Q4 and full-year 2024 financial results, highlighting significant progress in its PBFT02 program for FTD-GRN patients. Interim data showed promising results, with Dose 1 PBFT02 increasing CSF progranulin levels from below 3 ng/mL to 13-27 ng/mL at six months and 22-34 ng/mL at 12 months.

The company has enrolled its first patient for Dose 2 PBFT02, which is 50% lower than Dose 1. Financial results show cash position of $76.8 million as of December 31, 2024, with runway extended into Q1 2027. Net loss for 2024 was $64.8 million ($1.07 per share), improved from $102.1 million in 2023. R&D expenses decreased to $40.2 million from $61.4 million, while G&A expenses reduced to $25.0 million from $41.6 million year-over-year.

Passage Bio (NASDAQ: PASG), a clinical stage genetic medicines company specializing in neurodegenerative diseases, has announced its participation in two major upcoming investor conferences.

The company will present at the TD Cowen 45th Annual Health Care Conference in Boston on March 5, 2025, at 9:10 a.m. ET, and the Leerink Global Biopharma Conference in Miami on March 12, 2025, at 8:00 a.m. ET. Both events will feature management presentations and investor meetings.

Interested parties can access live webcasts of the presentations through the Investors & Media section of Passage Bio's website at investors.passagebio.com. Replay recordings will remain available for 30 days after each event.